AnaptysBio (NASDAQ:ANAB) Insider Sells $100,820.85 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul Lizzul sold 2,235 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $45.11, for a total value of $100,820.85. Following the completion of the transaction, the insider directly owned 37,213 shares in the company, valued at $1,678,678.43. This represents a 5.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AnaptysBio Price Performance

NASDAQ ANAB opened at $44.67 on Friday. The stock has a market capitalization of $1.24 billion, a P/E ratio of -15.84 and a beta of 0.32. The business has a 50 day simple moving average of $42.62 and a 200 day simple moving average of $31.51. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $52.47.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. Equities analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has initiated a share buyback plan on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in shares of AnaptysBio in the fourth quarter worth approximately $506,000. Tudor Investment Corp ET AL grew its holdings in AnaptysBio by 47.2% during the third quarter. Tudor Investment Corp ET AL now owns 13,869 shares of the biotechnology company’s stock worth $425,000 after buying an additional 4,450 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its position in AnaptysBio by 2.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company’s stock valued at $11,588,000 after buying an additional 10,005 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in AnaptysBio during the 3rd quarter valued at $315,000. Finally, Larson Financial Group LLC boosted its holdings in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares during the last quarter.

Key AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

Wall Street Analyst Weigh In

ANAB has been the topic of several research reports. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Wells Fargo & Company boosted their target price on AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. HC Wainwright dropped their price target on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Monday, November 24th. UBS Group began coverage on AnaptysBio in a research note on Wednesday. They issued a “buy” rating and a $70.00 price objective for the company. Finally, Barclays lowered their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average target price of $60.40.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.